Thomas Darton

University of Sheffield - Department of Infection, Immunity and Cardiovascular Disease

17 Mappin Street

Sheffield, Sheffield S1 4DT

United Kingdom

SCHOLARLY PAPERS

4

DOWNLOADS
Rank 364

SSRN RANKINGS

Top 364

in Total Papers Downloads

53,696

SSRN CITATIONS

3

CROSSREF CITATIONS

2

Scholarly Papers (4)

1.

Single Dose Administration, And The Influence Of The Timing Of The Booster Dose On Immunogenicity and Efficacy Of ChAdOx1 nCoV-19 (AZD1222) Vaccine

Number of pages: 37 Posted: 01 Feb 2021
University of Oxford - Oxford Vaccine Group, University of Siena - Institute of Global Health, University of the Witwatersrand - South African Medical Research Council Vaccines and Infectious Diseases Analytical Research Unit, Federal University of Sao Paulo, University of Oxford - Jenner Institute, University of Oxford - Oxford Vaccine Group, University of Oxford - Jenner Institute, University of the Witwatersrand, Soweto Clinical Trials Centre, Soweto Clinical Trials Centre, University of Oxford - Oxford Vaccine Group, Setshaba Research Centre, University of Oxford - Jenner Institute, University of Oxford - Oxford Vaccine Group, Liverpool School of Tropical Medicine - Department of Clinical Sciences, University of the Witwatersrand - South African Medical Research Council Vaccines and Infectious Diseases Analytical Research Unit, University of Sheffield - Department of Infection, Immunity and Cardiovascular Disease, University of Cape Town - Centre for Lung Infection and Immunology, University of Oxford - Jenner Institute, Newcastle upon Tyne Hospitals NHS Foundation Trust - Department of Infection and Tropical Medicine, University of Oxford - Oxford Vaccine Group, University of Oxford - Jenner Institute, University of Oxford - Jenner Institute, Wits Reproductive Health & HIV Institute (WRHI), University of Southampton - NIHR Southampton Clinical Research Facility and Biomedical Research Centre, University of Oxford - Oxford Vaccine Group, Liverpool School of Tropical Medicine - Department of Clinical Sciences, University Hospitals Bristol and Weston NHS Foundation Trust, University of London - St George's Vaccine Institute, University College London - Department of Infection, University of Oxford - Clinical BioManufacturing Facility, University Hospitals Birmingham NHS Foundation Trust, University of Oxford - Oxford Vaccine Group, University of the Witwatersrand - South African Medical Research Council, Liverpool School of Tropical Medicine - Department of Clinical Sciences, AstraZeneca Pharmaceuticals, University of the Witwatersrand - South African Medical Research Council, University of Oxford - Jenner Institute, University of Oxford - Oxford Vaccine Group, University of the Witwatersrand - South African Medical Research Council, University of the Witwatersrand - South African Medical Research Council, North Bristol NHS Trust - Severn Pathology, NIHR UCLH Clinical Research Facility, Hull University Teaching Hospitals NHS Trust, University of Oxford - Oxford Vaccine Group, AstraZeneca Pharmaceuticals, Braziland Hospital São Rafael - Escola Bahiana de Medicina e Saúde Pública, Universidade Federal do Rio Grande do Norte (UFRN), University of Oxford - Jenner Institute, London Northwest University Healthcare, University of Oxford - Oxford Vaccine Group, University of the Witwatersrand - Perinatal HIV Research Unit, Setshaba Research Centre, University of Oxford - Oxford Vaccine Group, Hospital Quinta D'OR, University of Oxford - Oxford Vaccine Group, NIHR Imperial Clinical Research Facility, University of Oxford - Oxford Vaccine Group, University of Oxford - Oxford Vaccine Group, Federal University of Santa Maria (UFSM) - Clinical Research Unit, University of Glasgow - College of Medical, Veterinary & Life Sciences, University of Oxford - Oxford Vaccine Group, University of Oxford - Oxford Vaccine Group, Universidade Federal do Rio Grande do Sul, Western General Hospital - Clinical Infection Research Group, Queen Elizabeth University Hospital, University of Cambridge - Department of Medicine, Royal Papworth Hospital - Heart Lung Research Institute, University of Nottingham, AstraZeneca Pharmaceuticals, AstraZeneca Pharmaceuticals, AstraZeneca Pharmaceuticals, Anuerin Bevan University Health Board, University of Oxford - Wellcome Trust Centre for Human Genetics, University of Oxford - Jenner Institute, University of Oxford - The Jenner Institute, University of Oxford - Oxford Vaccine Group and affiliation not provided to SSRN
Downloads 45,051 (35)
Citation 3

Abstract:

Loading...

2.

Efficacy of ChAdOx1 nCoV-19 (AZD1222) Vaccine Against SARS-CoV-2 VOC 202012/01 (B.1.1.7)

Number of pages: 40 Posted: 04 Feb 2021
University of Oxford - Oxford Vaccine Group, University of Oxford - Big Data Institute, University of Oxford - Oxford Vaccine Group, University of Cambridge, University of Oxford - Jenner Institute, University of Oxford - Oxford Vaccine Group, University of Cambridge, University of Oxford - Wellcome Centre for Human Genetics, University of Oxford - Jenner Institute, Public Health England - National Infection Service, University of Oxford - Oxford Vaccine Group, Liverpool School of Tropical Medicine - Department of Clinical Sciences, UK Biocentre, University of Sheffield - Department of Infection, Immunity and Cardiovascular Disease, University of Oxford - Oxford Vaccine Group, University of Oxford - Jenner Institute, Newcastle upon Tyne Hospitals NHS Foundation Trust - Department of Infection and Tropical Medicine, University of Oxford - Jenner Institute, University of Oxford - Jenner Institute, University of Southampton - NIHR Southampton Clinical Research Facility and Biomedical Research Centre, Liverpool School of Tropical Medicine - Department of Clinical Sciences, University of Oxford - Oxford Vaccine Group, University Hospitals Bristol and Weston NHS Foundation Trust, University of Oxford - Jenner Institute, University of Oxford - Jenner Institute, University of London - St George's Vaccine Institute, University College London - Department of Infection, University of Oxford - Clinical BioManufacturing Facility, University Hospitals Birmingham NHS Foundation Trust, University of Oxford - Oxford Vaccine Group, Public Health England - National Infection Service, University of London - St George's Vaccine Institute, Queen Elizabeth University Hospital, Liverpool School of Tropical Medicine - Department of Clinical Sciences, University of Oxford - Jenner Institute, University of Oxford - Oxford Vaccine Group, North Bristol NHS Trust - Severn Pathology, NIHR UCLH Clinical Research Facility, Hull University Teaching Hospitals NHS Trust, University of Cambridge, University of Oxford - Oxford Vaccine Group, University of Oxford - Jenner Institute, London Northwest University Healthcare, University of Oxford - Oxford Vaccine Group, University of Oxford - Oxford Vaccine Group, University of Oxford - Oxford Vaccine Group, NIHR Imperial Clinical Research Facility, University of Oxford - Oxford Vaccine Group, University of Glasgow - College of Medical, Veterinary & Life Sciences, University of Oxford - Oxford Vaccine Group, University of Oxford - Oxford Vaccine Group, Western General Hospital - Clinical Infection Research Group, Queen Elizabeth University Hospital, Royal Papworth Hospital - Heart Lung Research Institute, University of Nottingham, AstraZeneca Pharmaceuticals, AstraZeneca Pharmaceuticals, Anuerin Bevan University Health Board, University of Oxford - Wellcome Trust Centre for Human Genetics, University of Oxford - Jenner Institute, University of Oxford - The Jenner Institute, University of Oxford - Oxford Vaccine Group, University of Oxford - Oxford Vaccine Group, University of Oxford - Oxford Vaccine Group, affiliation not provided to SSRN and affiliation not provided to SSRN
Downloads 8,362 (790)
Citation 5

Abstract:

Loading...

3.

Ethical Payment to Participants in Human Infection Challenge Studies, with a Focus on SARS-CoV-2: Report and Recommendations

Number of pages: 116 Posted: 16 Aug 2020
Department of Medical Ethics and Health Policy, Perelman School of Medicine, University of Pennsylvania, University of Sheffield - Department of Infection, Immunity and Cardiovascular Disease, University of Pennsylvania - Perelman School of Medicine, Independent, Bank of America, Faculty of Law & Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, University of Sheffield, Dept. of Economics, Stanford University, University of Arkansas for Medical Sciences - College of Medicine and Independent
Downloads 283 (128,696)
Citation 4

Abstract:

Loading...

human infection challenge study, challenge trial, SARS-CoV-2, COVID-19, coronavirus, research, payment

4.

Decision Analysis Approach to Risk/Benefit Evaluation in the Ethical Review of Controlled Human Infection Studies

Bioethics, Vol. 34, Issue 8, pp. 764-770, 2020
Number of pages: 7 Posted: 20 Oct 2020
Michael Yu, Thomas Darton and Jonathan Kimmelman
McGill University, University of Sheffield - Department of Infection, Immunity and Cardiovascular Disease and McGill University - BioMedical Ethics Unit
Downloads 0 (774,963)
  • Add to Cart

Abstract:

Loading...

controlled human infection, decision analysis, research ethics, risk and benefit, vaccine development